|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.345 USD | +0.55% |
|
+5.34% | -5.65% |
| 05-13 | Harvard Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| 05-12 | Harvard Bioscience, Inc., Q1 2026 Earnings Call, May 12, 2026 |
Company Valuation: Harvard Bioscience, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 287.7 | 115.4 | 228.4 | 92.03 | 29.81 | 28.46 | - |
| Change | - | -59.89% | 97.92% | -59.7% | -67.6% | -4.55% | - |
| Enterprise Value (EV) | 287.7 | 115.4 | 228.4 | 92.03 | 29.81 | 28.46 | 28.46 |
| Change | - | -59.89% | 97.92% | -59.7% | -67.6% | -4.55% | 0% |
| P/E | -705x | -12x | -66.9x | -7.54x | -0.52x | -3.22x | -14.3x |
| PBR | 3.65x | 1.64x | 3.18x | 1.47x | 2.16x | 3.73x | 5.39x |
| PEG | - | -0x | 1x | -0x | -0x | 0x | 0.2x |
| Capitalization / Revenue | 2.42x | 1.02x | 2.03x | 0.98x | 0.34x | 0.32x | 0.3x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 0.32x | 0.3x |
| EV / EBITDA | 0x | 0x | 0x | 0x | 0x | 3.31x | 3.03x |
| EV / EBIT | 0x | 0x | 0x | 0x | 0x | 4.59x | 3.31x |
| EV / FCF | 0x | -0x | 0x | -0x | 0x | -9.81x | -142x |
| FCF Yield | 0.02% | -0.38% | 5.36% | -1.31% | 18.3% | -10.2% | -0.7% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.1 | -2.3 | -0.8 | -2.8 | -12.8 | -1.96 | -0.44 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 118.9 | 113.3 | 112.2 | 94.14 | 86.55 | 88.6 | 94.2 |
| EBITDA 1 | 18.5 | 10.84 | 14.55 | 7.196 | 8.081 | 8.6 | 9.4 |
| EBIT 1 | 16.72 | 9.497 | 13.11 | 5.294 | 6.163 | 6.2 | 8.6 |
| Net income 1 | -0.288 | -9.516 | -3.415 | -12.4 | -56.7 | -9.05 | -2.05 |
| Net Debt | - | - | - | - | - | - | - |
| Reference price 2 | 70.500 | 27.700 | 53.500 | 21.100 | 6.688 | 6.310 | 6.310 |
| Nbr of stocks (in thousands) | 4,081 | 4,166 | 4,269 | 4,362 | 4,458 | 4,510 | - |
| Announcement Date | 08/03/22 | 09/03/23 | 07/03/24 | 12/03/25 | 12/03/26 | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.22x | - | - | - | 28.46M | |
| 28.59x | 5.1x | 19.54x | 0.32% | 212B | |
| 33.1x | 6.03x | 19.11x | 0.74% | 139B | |
| 41.19x | 10.71x | 23.67x | -.--% | 133B | |
| 17.99x | 3.72x | 12.09x | -.--% | 70.19B | |
| 35.1x | 7.05x | 22.3x | -.--% | 51.14B | |
| 19.89x | 2.33x | 11.77x | 2.58% | 50.09B | |
| 27.19x | 5.41x | 18.48x | 0.73% | 39.48B | |
| 45.45x | 6.34x | 19.48x | -.--% | 36.79B | |
| 40.69x | 6.53x | 23.1x | -.--% | 29.92B | |
| Average | 28.60x | 5.91x | 18.84x | 0.49% | 76.14B | |
| Weighted average by Cap. | 31.71x | 6.20x | 19.25x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- HBIO Stock
- Valuation Harvard Bioscience, Inc.
Select your edition
All financial news and data tailored to specific country editions
